EP1543036A4 - Protein for diagnosing diabetic retinopathy - Google Patents

Protein for diagnosing diabetic retinopathy

Info

Publication number
EP1543036A4
EP1543036A4 EP03708726A EP03708726A EP1543036A4 EP 1543036 A4 EP1543036 A4 EP 1543036A4 EP 03708726 A EP03708726 A EP 03708726A EP 03708726 A EP03708726 A EP 03708726A EP 1543036 A4 EP1543036 A4 EP 1543036A4
Authority
EP
European Patent Office
Prior art keywords
protein
diabetic retinopathy
immunoglobulin
diabetic
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03708726A
Other languages
German (de)
French (fr)
Other versions
EP1543036A1 (en
Inventor
Won Il Yoo
Sung Ho Lee
Kunewoo Park
Yang Je Cho
Bo Young Ahn
Oh Woong Kwon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kuhnil Pharmaceutical Co Ltd
Eyegene Inc
Original Assignee
Kuhnil Pharmaceutical Co Ltd
Eyegene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR2002041771 priority Critical
Priority to KR20020041771 priority
Application filed by Kuhnil Pharmaceutical Co Ltd, Eyegene Inc filed Critical Kuhnil Pharmaceutical Co Ltd
Priority to PCT/KR2003/000544 priority patent/WO2004007554A1/en
Publication of EP1543036A1 publication Critical patent/EP1543036A1/en
Publication of EP1543036A4 publication Critical patent/EP1543036A4/en
Application status is Withdrawn legal-status Critical

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/04Endocrine or metabolic disorders
    • G01N2800/042Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/16Ophthalmology
    • G01N2800/164Retinal disorders, e.g. retinopathy

Abstract

The present invention relates to material for diagnosing Diabetic retinopathy. More particularly, the present invention relates to Immunoglobulin A protein for diagnosing Diabetic retinopathy, kit for diagnosing Diabetic retinopathy comprising antibody against the protein and method for diagnosing Diabetic retinopathy. The present invention can be used as diagnosing Diabetic retinopathy.

Description

PROTEIN FOR DIAGNOSING DIABETIC RETINOPATHY

[Technical Field]

The present invention generally relates to diagnostic substances for diabetic retinopathy, and more specifically, to a diagnostic kit including an Immunoglobulin A protein and an antibody thereof, and a diagnostic method using the same .

[Background of the Invention]

In general, diabetes mellitus as a complex metabolic disorder causing microangiopathy is one of systemic diseases which broadly impair systemic tissues. Diabetes may affect vision, and most importantly, damage to blood vessels inside the eye (LEE Tae-hee, CHOI Young-gil. Diabetic Vascular Complications, Seoul: Koryo Medicine) . Diabetic retinopathy, one of the most severe complications, becomes an important problem as life span and prevalence period of diabetic patients become longer due to improvement of living standards and development of treatment (Klein R. et al . , Arch Ophthalmol. 102:520-532(1984)). Diabetic retinopathy has two stages a nonproliferative stage and a proli erative stage. The nonproliferative stage is characterized in that retinal lesions resulting from vascular disorders are limited in retina. The proliferative stage is characterized by penetration of neovascularization tissues from retina into the vitreous cavity (Green, In: Spencer H, ed . Ophtalmic Pathology: an atlas and textbook. 4th ed. Philadelphia: B Saunder; 1124-1129 (1996)). Diabetic retinopathy is diagnosed by observation of characteristic changes in the fundus structure. Vision loss due to diabetic retinopathy results from haemorrhagia corporis vitrei and maculopathy with traction retinal detachment of yellow spot in the proliferative stage. Laser treatment with surgery treatment is well-known for its effectiveness for the vision loss (Diabetic Retinopathy Study Report Number 14: Int Ophthalmol Clin. 27:239-253(1987)). This treatment following proper steps can prevent vision loss, minimizing side effects. Diabetic retionpathy should be frequently examined and diagnosed to determine whether operation is performed on the diabetic retinopathy or not. However, since diabetic retinopathy is currently diagnosed only by funduscopy, it is difficult to detect diabetic retinopathy in its early stages. As a result, it is highly frequent for patients to miss opportunities to prevent the diabetic retinopathy and have an operation on it. Accordingly, a method is disclosed for diagnosing diabetic retinopathy easily in blood. There has been no method for diagnosing diabetic retinopathy using blood. The present inventors found a protein which varies in blood by using proteomics, and applied the protein to diagnosis. Since this protein shows a marked quantitative change between a diabetic patient with no diabetic retinopathy complication and a diabetic patient having a complication, the present invention comprising this protein is completed using accurate quantification by immunological method

[Detailed Description of the Invention]

In order to overcome the above-described problems, the present invention has an object to provide a useful diagnosis for diabetic retinopathy.

The present invention has another object to provide a kit for diagnosing diabetic retinopathy including the diagnosis .

The present invention has still another object to provide a method for diagnosing diabetic retinopathy. In order to achieve the above-described ob ects, there is provided an immunoglobulin A protein, which is effective for diagnosing diabetic retinopathy, and a protein fragment thereof . A sequence obtained by protein analysis corresponds to a constant site of immunoglobulin A heavy chain. The immunoglobulin A protein exists as heavy-chain and light- chain types. Since each chain has a variable region, the protein has sites having many different sequences. As a result, protein having a sequence, which may be determined as an immunoglobulin A protein, can be obtained.

The disclosed immunoglobulin A protein may have various ammo acid sequences as well as SEQ ID NO : 1 of heavy chain . The amino acid sequence of H chain of Ig A is as described n SEQ ID NO:l.

The disclosed protein fragment of the immunoglobulin A can have various types of fragment including a peptide of SEQ ID NO:2. There is provided an antibody specifically binding the protein. The antibody may be both polyclonal and monoclonal, but more preferably monoclonal.

There is also provided a kit for diagnosing diabetic retinopathy including the antibody. The disclosed kit further comprises the antibody protein obtained by conjugating with enzyme peroxidase, alkaline phosphatase or biotm.

The rest reagents used in the disclosed diagnosis kit can be easily obtained from ingredients used in general diagnosis kits.

There is also provided a method for diagnosing diabetic retinopathy, comprising: a) treating the antibody with a blood sample and an anti-Immunoglobulm A protein conjugated with peroxidase, alkaline phosphatase or biotin; and b) measuring optical density of the compound, wherein diabetic retinopathy is diagnosed when the measured result represents below 400mg/dL immunoglobulin A. There are provided an Immunoglobulin A gene of SEQ ID NO: 3 for coding an immunoglobulin A protein and a nucleotide of SEQ ID NO: 4 for coding a peptide of SEQ ID NO : 2.

Hereinafter, the present invention will be described in detail . In the present invention, the immunoglobulin A protein of vitreous body in eyeball of diabetic retinopathy patients is shown to increase than that in healthy vitreous body. Here, the present inventor found that the protein changed in blood, that is, the immunoglobulin A protein of diabetic retinopathy patient decreases in blood than that of diabetic patients. Accordingly, a diagnosis for diabetic retinopathy is disclosed using an immunologic method.

In order to accomplish the above-described object, protein groups, which show specific changes to diabetic retinopathy, are analyzed using a proteomics method. The following results are found by analyzing quantitative changes of the proteins and the types of proteins in vitreous bodies of diabetic retinopathy patients and normal vitreous bodies. After the changes of the target protein is checked in blood, a kit for diagnosing diabetic retinopathy is prepared using a proper immunological method. First, a normal vitreous body is settled as a control group. The protein groups, which show qualitative and quantitative differences, are isolated in vitreous bodies obtained from diabetic patients and diabetic retinopathy patients by two- dimensional gel separation and image analysis. The protein groups are identified using MS and Q-TOF analyzers. The protein wherein changes were observed and identified is proved as Immunoglobulin A. Increase of Immunoglobulin A, which is hardly observed in normal vitreous body, of vitreous body in diabetic retinopathy patients was observed. However, it has not been reported that immunoglobulin A increases in vitreous body of diabetic retinopathy patients. Second, this protein showed quantitative changes in blood. When blood of diabetic patients is a control group, immunoglobulin A decreases in blood of diabetic retinopathy patients. However, this result has not been reported, either. Third, a easy, sensitive and precise method for measuring existential values of proteins is selected by preparing a kit via an immunological method.

Hereinafter, the present invention will be described in detail according to preferred embodiments.

[Brief Description of the Drawings]

Fig. 1 is a diagram illustrating a process for pre- processing vitreous body of eyeball to be applied to proteomics .

F g. 2 shows gel pictures illustrating CBB-stamed fundus vitreous body proteins after two-dimensional electrophoresis . The proteins are not showed in the marked region in a vitreous body of normal eyeball while the proteins are showed in the marked region in a vitreous body of diabetic retinopathy eyeball.

Fig. 3 shows CBB-stained gel pictures illustrating serum proteins of a diabetic retinopathy patient and a diabetic patient alone, the proteins CBB-stamed after two- dimensional electrophoresis. The excessive amount of protein exists in marked region for diabetic patient alone while the decreased amount of protein be showed in the marked region for diabetic retinopathy patient.

Fig. 4 shows a graph illustrating the mass spectrum

(A) of peptides treated with trypsm among proteins of the marked region of Fig. 2 using MALDI-TOF and Q-TOF analyzer, and the ammo sequences of the peptide among the peptide fragments (B) .

Fig. 5 shows a standard titration graph illustrating 0, 15.6, 31.25, 62.5, 125, 250, 500ng/ml immunoglobulin A standard solution and measured optical density values after ELISA reaction.

[Preferred Embodiments]

Example 1 : Sample preparation of vitreous body for analyzing proteomics Diabetic retinopathy is one of complications resulting from long-term diabetes. Diabetic retinopathy is characterized by generation of many abnormal neovascular systems having incomplete vascular structures, which causes bleeding in vitreous body of eyeball . The bleeding results in abnormality in retina, and further weakness and loss of eyesight. In the present invention, disease indicator was searched, and information on proteins for representing disease state was obtained by analyzing proteins in vitreous bodies of a normal control group and diabetic retinopathy patients, using a proteomics method. First to apply the proteomics method to the proteins, vitreous body was treated to be easy to analyze. The vitreous body contains large amount of high molecular weight mucopolysacchaπde, hyaluronic acid. However, this polysaccharide was proved to interrupt protein separation. As a result, a method was devised to remove this polysaccharide effectively (see F g. 1) . First, 4ml vitreous body was diluted with 16ml distilled water, and put the diluent in a tube having a cut- off membrane of 1,000,000 and centrifuged 8,000rpm at 4°C for 2 hours. This procedure was repeated three times to filter high molecular weight polysaccharide over 1,000,000 by difference of molecular weight. The non-filtered proteins were put in a tube having a 10,000 cut-off membrane and centrifuged 4,000rpm, at 4°C and then concentrated for analysis. The method for removing high molecular weight polysaccharide in the present invention enabled effective analysis by solving the problem that was not easily isolated in low pH .

Example 2 : Investigate of protein groups changed in vitreous bodies of eyeball obtained from normal person and diabetic retinopathy patient Proteins were isolated from each vitreous body and concentrated at lmg/mL for analysis. First, the proteins were two-dimensionally separated by a stepwise method using two different characteristics of proteins. In the first step, proteins were moved according to net charge of the proteins by applying electrical stimulus to the proteins (IEF, pH 3-10) . In the second step, proteins were moved on acrylamide gel (8-18%) according to molecular weight of each protein. One-dimensional electrophoresis (protein movement according to pH) was performed on the proteins with 50mA per gel for 12 hours. Then, two-dimensional electrophoresis (protein movement according to molecular weight) was performed on the proteins on poly-acrylamide with 50mA per gel for 6 hours. These moved proteins were stained with a Coomaasie Brilliant Blue-G250 stain and a silver-staining method for visualizing. The difference of proteins between in normal vitreous body and in vitreous body of diabetic retinopathy patient was analyzed by using image analysis software, Phoretix (Nonlinear dynamics, UK), in computer. From analyzing the proteins m two groups, the present inventors confirmed that the protein group showing a difference existed (see Figs. 2 and 3) .

Example 3 : Identification of serum proteins that show the difference between diabetic patient and diabetic retinopathy patient

Proteins having differences m quantity and quality were searched and identified by MALDI-TOF and Q-TOF analyzers to know kinds of the proteins (see Fig. 4) . It was shown that the amount of immunoglobulin A decreased m blood of diabetic retinopathy than blood of diabetic patient.

Example 4 : Diagnosis of diabetic retinopathy by enzyme- linked immunosorbent assay (ELISA)

The present study was performed to find out whether serum of diabetic retinopathy among diabetic patients could be distinguished by Sandwich enzyme immunosorbent assay (ELISA) using anti-immunoglobulm A antibody. Serums were obtained from 10 normal healthy persons, 45 diabetic patients having no diabetic retinopathy and 86 diabetic retinopathy patients in hospital. First, lOOul of anti- lmmunoglobulm A (Koma, Korea) (lug antibody protein per well; final concentration lOug/ml) dissolved with coating buffer (50mM NaHC03, pH 9.0) per well was reacted and coated in a EIA 96 well plate at room temperature for 1 hour. The each well was washed twice for 10 minutes with 400ul PBST, and then post-coated with PBS including 1% BSA. lOOul Serum of patients diluted with PBST buffer was put to the each well, reacted for 1 hour, and then washed five times with PBS. lOOul of diluted peroxidase conjugated-anti- lmmunoglobulm A antibody (KOMA Biotech Inc., Korea) was put into the each well, and then reacted for 1 hour. After reaction, the each well was washed three times with PBS. Then, lOOul 0.1M citrate-phosphate (pH 4.9) containing lmg/ml OPD (O-phenylenediamine dihydrochloride) and 0.03% H202 was put '-therein, and reacted at room temperature for 20~30 minutes. The reaction was stopped by lOOul of 3M sulfuric acid, and optical density was measured at 450nm using an ELISA reader. The amount of immunoglobulin A per blood unit volume (ml) was determined through applying conversion by standard titration curve and dilution rate to the optical density (see Fig. 5) . As a result of ELISA measurement, the amount of immunoglobulin A ranged from 131.2 to 298.7 mg/dL in serum of normal person, from 226.5 to 771.9mg/dL in serum of diabetic patient, and from 105.3 to 557.2mg/dL in serum of diabetic retinopathy patient. These results were shown as average values in Table 1. As the measurement average value of immunoglobulme A, 217.6 ± 82. lmg/dL was shown in normal person, 457.6 ± 151.6mg/dL in diabetic patient, 244.4 ± 117.1mg/dL in non-proliferative diabetic retinopathy patient, and 278.6 ± 123.6 mg/dL in proliferative diabetic retinopathy. Here, it was remarkably shown that the large amount of immunoglobulin A existed in serum of the diabetic patient group. However, it was shown that there was little difference in the amount of immunoglobulin A in serum of non-proliferative and proliferative diabetic retinopathy patient. If diabetic retinopathy was decided as positive when the amount of immunoglobulin A was below 400mg/dL of ELISA value, 72 of 86 persons were proved as patients. Here, 83.7% of diagnostic sensitivity was shown. In case of diabetic patients without retinopathy, 22 of 45 persons were proved as patient. Here, [Table 1] Average value of measuring immunoglobulin A in serum of healthy person and patient via ELISA

[Table 2] Judgement of diabetic retinopathy patient via ELISA standard 400mg/dL (cut off)

[Industrial Applicability]

The present invention relates to a technology for easily diagnosing diabetic retinopathy which is a complication of diabetic mellitus . There has been no effective commercial diagnostic for diabetic retinopathy. Diabetic retinopathy has been diagnosed absolutely by oculists in hospital. It is impossible for diabetic patients to diagnose diabetic retinopathy in its early stage without regular ophthalmic examination and optical defect by subjective symptoms. The present diagnostic is characterized by simple blood test, and very effective in that the development of complications can be identified before ophthalmic examination. Particularly, the present invention is advantageous in its cheap cost and simple treatment for a plurality of diabetic patients who take medical tests or consult physicians by adapting ELISA method using 96 wells which enable mass test. Also, the present invention is excellent m its accuracy and precision by using an immunochemical method. In conclusion, the present invention is effective for diagnosis of diabetic retinopathy in its early diagnosis and screening, and helpful for latent and early diabetic retinopathy patients in their decision of medication time, thereby delaying disease to severe diabetic retinopathy.

Claims

[What is Claimed is]
1. An Immunoglobulin A protein and an analogous protein or a protein fragment thereof described in SEQ ID NO : 1 wherein the protein is effective for diagnosing diabetic retionpathy.
2. The protein fragment according to claim 1, wherein the protein fragment comprises a peptide sequence described in SEQ ID NO: 2. 3. An antibody specifically binding the protein of claim 1 or 2.
4. A kit for diagnosing diabetic retinopathy comprising the antibody of claim 3.
5. The kit according to claim 4, further comprising enzyme peroxidase, alkaline phosphatase or biotin conjugated-anti-Immunoglobulin A antiboody.
6. A method for diagnosing diabetic retinopathy, comprising : a) treating the antibody of claim 2 with a blood sample and an peroxidase, alkaline phosphatase or biotin conjugated-anti-Immunoglobulin A protein; and b) measuring optical density of the compound, wherein diabetic retinopathy is diagnosed when the measured value represents optical density (ELISA value) lower than normal one.
7. An Immunoglobulin A gene and an analogous gene of SEQ ID NO: 3 for coding the protein of claim 1 or 2.
EP03708726A 2002-07-16 2003-03-20 Protein for diagnosing diabetic retinopathy Withdrawn EP1543036A4 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
KR2002041771 2002-07-16
KR20020041771 2002-07-16
PCT/KR2003/000544 WO2004007554A1 (en) 2002-07-16 2003-03-20 Protein for diagnosing diabetic retinopathy

Publications (2)

Publication Number Publication Date
EP1543036A1 EP1543036A1 (en) 2005-06-22
EP1543036A4 true EP1543036A4 (en) 2006-07-05

Family

ID=30113191

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03708726A Withdrawn EP1543036A4 (en) 2002-07-16 2003-03-20 Protein for diagnosing diabetic retinopathy

Country Status (8)

Country Link
US (1) US20060240484A1 (en)
EP (1) EP1543036A4 (en)
JP (1) JP2006506606A (en)
KR (1) KR100528664B1 (en)
CN (1) CN1675246A (en)
AU (1) AU2003212700A1 (en)
CA (1) CA2492980A1 (en)
WO (1) WO2004007554A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2414401B (en) 2004-05-28 2009-06-17 Cilag Ag Int Injection device
GB2414406B (en) 2004-05-28 2009-03-18 Cilag Ag Int Injection device
GB2414409B (en) 2004-05-28 2009-11-18 Cilag Ag Int Injection device
GB2414400B (en) 2004-05-28 2009-01-14 Cilag Ag Int Injection device
GB2414402B (en) 2004-05-28 2009-04-22 Cilag Ag Int Injection device
GB2414403B (en) 2004-05-28 2009-01-07 Cilag Ag Int Injection device
GB2414399B (en) 2004-05-28 2008-12-31 Cilag Ag Int Injection device
GB2414775B (en) 2004-05-28 2008-05-21 Cilag Ag Int Releasable coupling and injection device
JP2006528361A (en) * 2004-07-06 2006-12-14 クンイル ファーマシューティカル カンパニー リミテッド Retinal vascular disease diagnostic composition comprising an aldolase and methods the diagnosis
JP2006154829A (en) 2004-12-01 2006-06-15 Lg Electronics Inc Plasma display panel
GB2424838B (en) 2005-04-06 2011-02-23 Cilag Ag Int Injection device (adaptable drive)
GB2425062B (en) 2005-04-06 2010-07-21 Cilag Ag Int Injection device
GB2427826B (en) 2005-04-06 2010-08-25 Cilag Ag Int Injection device comprising a locking mechanism associated with integrally formed biasing means
GB2424836B (en) 2005-04-06 2010-09-22 Cilag Ag Int Injection device (bayonet cap removal)
GB2424835B (en) 2005-04-06 2010-06-09 Cilag Ag Int Injection device (modified trigger)
ES2340936T3 (en) 2005-08-30 2010-06-11 Cilag Gmbh International Needle mounting system for prefilled syringe.
US20110098656A1 (en) 2005-09-27 2011-04-28 Burnell Rosie L Auto-injection device with needle protecting cap having outer and inner sleeves
CN101484803A (en) * 2006-01-27 2009-07-15 乔治梅森大学 Ocular fluid markers
KR100866579B1 (en) * 2006-06-01 2008-11-11 아이진 주식회사 Kit for diagnosing diabetic retinopathy
GB2438590B (en) 2006-06-01 2011-02-09 Cilag Gmbh Int Injection device
GB2438593B (en) 2006-06-01 2011-03-30 Cilag Gmbh Int Injection device (cap removal feature)
GB2438591B (en) 2006-06-01 2011-07-13 Cilag Gmbh Int Injection device
KR100961926B1 (en) * 2007-08-30 2010-06-10 서울대학교산학협력단 Biomarker composition for detecting diabetic retinopathy and diagnostic kit therefor
GB2461089B (en) 2008-06-19 2012-09-19 Cilag Gmbh Int Injection device
GB2461086B (en) 2008-06-19 2012-12-05 Cilag Gmbh Int Injection device
GB2461087B (en) 2008-06-19 2012-09-26 Cilag Gmbh Int Injection device
GB2461084B (en) 2008-06-19 2012-09-26 Cilag Gmbh Int Fluid transfer assembly
GB2461085B (en) 2008-06-19 2012-08-29 Cilag Gmbh Int Injection device
CN105837666A (en) * 2015-12-30 2016-08-10 田梗 Protein for diagnosis of diabetic retinopathy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021658A1 (en) * 1999-09-24 2001-03-29 Human Genome Sciences, Inc. 32 human secreted proteins

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9805913D0 (en) * 1998-03-19 1998-05-13 Kings College University Of Lo Diagnosis of ms

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021658A1 (en) * 1999-09-24 2001-03-29 Human Genome Sciences, Inc. 32 human secreted proteins

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
EUN YOUNG LEE ET AL: "IMMUNOGLOBULIN A NEPHROPATHY IN PATIENTS WITH NON-INSULIN DEPENDENT DIABETES MELLITUS", JOURNAL OF KOREAN MEDICAL SCIENCE, KOREAN ACADEMY OF MEDICAL SCIENCE, SEOUL, KR, vol. 14, 1999, pages 582 - 585, XP008047555, ISSN: 1011-8934 *
KAWAMURA S ET AL: "Nucleotide sequence of the gorilla immunoglobulin alpha 1 gene.", NUCLEIC ACIDS RESEARCH. 25 AUG 1989, vol. 17, no. 16, 25 August 1989 (1989-08-25), pages 6732, XP002382012, ISSN: 0305-1048 *
NICOLOFF GEORGE ET AL: "Changes in the serum levels of anti-elastin antibodies are associated with the development of microvascular complications in children with Type 1 diabetes mellitus", CENTRAL-EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 26, no. 1, 2001, pages 17 - 23, XP002382011, ISSN: 1426-3912 *
RODRIGUEZ-SEGADE S ET AL: "High serum IgA concentrations in patients with diabetes mellitus: agewise distribution and relation to chronic complications.", CLINICAL CHEMISTRY. JUL 1996, vol. 42, no. 7, July 1996 (1996-07-01), pages 1064 - 1067, XP002381324, ISSN: 0009-9147 *
See also references of WO2004007554A1 *

Also Published As

Publication number Publication date
CN1675246A (en) 2005-09-28
WO2004007554A1 (en) 2004-01-22
KR100528664B1 (en) 2005-11-15
US20060240484A1 (en) 2006-10-26
JP2006506606A (en) 2006-02-23
CA2492980A1 (en) 2004-01-22
AU2003212700A1 (en) 2004-02-02
EP1543036A1 (en) 2005-06-22
KR20040007237A (en) 2004-01-24

Similar Documents

Publication Publication Date Title
Hampel et al. Core biological marker candidates of Alzheimer’s disease–perspectives for diagnosis, prediction of outcome and reflection of biological activity
Hayakawa et al. Neuromyelitis optica and anti-aquaporin-4 antibodies measured by an enzyme-linked immunosorbent assay
US7351524B2 (en) Diagnostics and therapeutics for macular degeneration-related disorders
Rota et al. Increased intrathecal TGF-β1, but not IL-12, IFN-γ and IL-10 levels in Alzheimer’s disease patients
JP4717810B2 (en) Biomarkers for identifying type 1 diabetes and type 2 diabetes mellitus
JP3259963B2 (en) Determination of p97 to diagnose and monitor Alzheimer's disease
EP1476758B2 (en) Detection and/or monitoring of synuclein-related diseases
US6451547B1 (en) Process for differential diagnosis of Alzheimer's dementia and device therefor
JP2002538463A (en) Methods for diagnosing and distinguishing stroke
US8741580B2 (en) Markers of renal transplant rejection and renal damage
Yang et al. New ELISAs with high specificity for soluble oligomers of amyloid β-protein detect natural Aβ oligomers in human brain but not CSF
JP2007506086A (en) Diagnostic method for brain damage-related diseases
KR100595494B1 (en) - diagnostic kit for alzheimer's disease using the level of anti-beta-amyloid antibody in blood
CA2501756C (en) Isolated post-translationally modified proteins for monitoring and diagnosing muscle damage
WO2009003142A1 (en) Beta2-microglobulin and c reactive protein (crp) as biomarkers for peripheral artery disease
KR100528664B1 (en) Composition for Diagnosing Diabetic Retinopathy and a kit for Diagnosing Diabetic Retinopathy comprising the same
EP1426764A1 (en) Method of diagnosing or monitoring saccharometabolic error
WO1998040748A1 (en) Diagnosing neurologic disorders
US20030175713A1 (en) Method for diagnosis of inflammatory diseases using CALGRANULIN C
JP2011522267A (en) Marker for graft failure and death
Kim et al. Differential expression of vitreous proteins in proliferative diabetic retinopathy
Shimizu et al. Plasma level of interleukin-6 is an indicator for predicting diabetic macular edema
US20030040660A1 (en) Method for diagnosing and distinguishing traumatic brain injury and diagnostic devices for use therein
US8030097B2 (en) Lipocalin-2 as a prognostic and diagnostic marker for heart and stroke risks
EP1543331A4 (en) Method of diagnosing alzheimer's disease

Legal Events

Date Code Title Description
AK Designated contracting states:

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent to

Countries concerned: ALLTLVMK

17P Request for examination filed

Effective date: 20050212

DAX Request for extension of the european patent (to any country) deleted
RIC1 Classification (correction)

Ipc: G01N 33/68 20060101AFI20060523BHEP

Ipc: G01N 33/58 20060101ALI20060523BHEP

A4 Despatch of supplementary search report

Effective date: 20060607

17Q First examination report

Effective date: 20070112

18D Deemed to be withdrawn

Effective date: 20071120